Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:44 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.
NCT04731298 · Swedish Orphan Biovitrum · PHASE2 · terminated · last registry update 2023-12-28 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor Decision related to Business Priorities, Assessment of Development Options” | – | Registry record, Swedish Orphan Biovitrum |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IFNG within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-03-12Results posted on the registry: Swedish Orphan Biovitrum, Emapalumab (NCT03312751)
- 2023-11-24Results posted on the registry: Swedish Orphan Biovitrum, NI-0501 + Saline (NCT04765553)
- 2023-10-06Results posted on the registry: Swedish Orphan Biovitrum, Emapalumab-Lzsg (NCT03985423)
- 2023-10-06Also stopped (terminated): Swedish Orphan Biovitrum, Emapalumab-Lzsg (NCT03985423)
- 2023-09-14Phase 3 first posted: Beijing Friendship Hospital, GTP regimen (NCT06038422)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision